Pulmonary Rehabilitation for Post-COVID Syndrome
(LHCRehab Trial)
Trial Summary
Do I have to stop taking my current medications for the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are taking an investigational drug, you must stop at least one month or six half-lives before the screening visit. Also, certain conditions like insulin or testosterone therapy, systemic corticosteroids, or HIV may affect your eligibility.
What data supports the idea that Pulmonary Rehabilitation for Post-COVID Syndrome is an effective treatment?
The available research shows that Pulmonary Rehabilitation, whether done remotely or in-person, is effective for people recovering from COVID-19. Studies have found that remote methods like telerehabilitation are just as beneficial as traditional in-person programs. These methods help improve symptoms and overall health, making them a good option for those who can't attend in-person sessions. This is especially important during the COVID-19 pandemic when many people have limited access to traditional rehabilitation centers.12345
What safety data exists for pulmonary rehabilitation for post-COVID syndrome?
The safety of pulmonary rehabilitation, including virtual and home-based methods, has been evaluated in various studies. These studies indicate that remotely based pulmonary rehabilitation, such as telerehabilitation and home-based programs, is feasible and effective for patients with lung diseases, including those recovering from COVID-19. Although there is variability in methods across studies, the existing data suggests that these alternative delivery methods do not compromise the effectiveness of traditional pulmonary rehabilitation. However, more high-quality studies are needed to further assess the safety, efficacy, and cost-effectiveness of these programs.12346
Is Virtual vs On Site Pulmonary Rehabilitation a promising treatment for Post-COVID Syndrome?
What is the purpose of this trial?
The purpose of the study is to assess the physiologic, immunologic, and mental health effects of a rehabilitation program on patients with Long Haul COVID (LHC).
Eligibility Criteria
Adults who've had COVID-19 at least 12 weeks ago and are experiencing Long Haul COVID with symptoms like fatigue, difficulty breathing, or exercise intolerance. They must be able to do a cardiopulmonary test. Excluded are those in other studies, recently on investigational drugs, unable to perform certain tests, severely desaturating during exercise testing, pregnant/nursing women, recent cancer treatments or significant other diseases.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo a 10-week rehabilitation program, either traditional pulmonary or virtual, based on their Post Exertional Malaise (PEM) status
Follow-up
Participants are monitored for changes in aerobic capacity, anxiety, sleep quality, quality of life, fatigue, dyspnea, post-exertional malaise, depression, and inflammatory markers
Treatment Details
Interventions
- Virtual vs On Site Pulmonary Rehabilitation
Virtual vs On Site Pulmonary Rehabilitation is already approved in United States, Canada, European Union for the following indications:
- Chronic Obstructive Pulmonary Disease (COPD)
- Post-COVID Syndrome (PCS)
- Other Chronic Respiratory Conditions
- COPD
- Chronic Lung Disease
- COPD
- Chronic Respiratory Conditions
Find a Clinic Near You
Who Is Running the Clinical Trial?
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Lead Sponsor